CAMBRIDGE, Mass. — Vyome Holdings, Inc. (NASDAQ: HIND), a clinical-stage healthcare holding company, announced that renowned medical oncologist Dr. Aditya Bardia has been appointed as Senior Medical Advisor to the company. In this consulting role, he will support the clinical development of Vyome’s lead asset, VT-1953, which is being developed to treat the symptoms of malignant fungating wounds (MFW). Approval for the therapy is targeted for 2026.
“I am excited to work with the Vyome team and guide the clinical development of VT-1953 for the treatment of symptoms of malignant fungating wound, a debilitating condition that can significantly impair quality of life for patients with cancer,” said Dr. Bardia. “In my clinical practice, I have seen patients suffer from this horrible condition, and we really need an effective treatment for this major unmet clinical need. I am encouraged by the preliminary data with VT-1953 in MFW, and the mechanistic basis for this therapy. This is the perfect opportunity to develop a first-in-class therapy, which can improve the quality of life for patients with cancer.”
Dr. Bardia has led clinical development efforts resulting in multiple drug approvals, including Sacituzumab Govitecan, Trastuzumab Deruxtecan and Datopotamab Deruxtecan. He also led the clinical development of Elacestrant, the first oral SERD approved for patients with metastatic HR-positive breast cancer. He trained in medical oncology at Johns Hopkins and subsequently joined Massachusetts General Hospital and Harvard Medical School as a faculty member before moving to the David Geffen School of Medicine at UCLA and UCLA Health Jonsson Comprehensive Cancer Center as Professor and director of the Breast Cancer Program and Translational Research Integration. He has received numerous awards and recognitions throughout his career.
“Dr. Bardia’s expertise in having led the development of multiple drugs and especially steering them through accelerated FDA approvals aligns with our strategy of designing robust, but cost-efficient, trials,” said Dr. Shiladitya Sengupta, Associate Professor of Medicine at Harvard Medical School and Co-Founder of Vyome. “We are delighted that Dr. Bardia decided to work with the Vyome team, significantly bolstering our depth in developing next-generation therapies, as we embark on pivotal studies with our lead asset.”
“The collaboration with Dr. Bardia marks an important milestone in Vyome’s growth journey. We have a brilliant team in place to unlock the next milestones of value in our lead program,” said Venkat Nelabhotla, CEO of Vyome.
